Controlled Release of Dexamethasone from Organosilicone Constructs for Local Modulation of Inflammation in Islet Transplantation

Jessica D. Weaver, Yun Song, Ethan Y. Yang, Camillo Ricordi, Antonello Pileggi, Peter Buchwald, Cherie L. Stabler

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Inflammation is a significant detriment to the engraftment of cells and tissues, particularly for islet transplantation, where a low tolerance for the inflammatory milieu results in significant graft loss. Local treatment with anti-inflammatories, such as glucocorticoids, provides the benefits of site-targeted delivery with minimization of the broad side effects associated with systemic delivery. Polydimethylsiloxane (PDMS) is a flexible platform that is capable of providing sustained delivery of hydrophobic drugs. Here, we evaluated the capacity of PDMS constructs loaded with the anti-inflammatory glucocorticoid dexamethasone (Dex) to locally mitigate inflammation in islet grafts. Dex-PDMS constructs, fabricated in rod or disk geometries, demonstrated prolonged and sustained release at therapeutically relevant levels. In vitro, Dex-PDMS constructs inhibited endotoxin-induced human monocyte and macrophage activation, but they did not impair islet viability or function. Dex-PDMS rods, co-transplanted with islet-seeded scaffolds in a murine model, demonstrated suppression of host inflammatory responses during early- and late-phase engraftment, without significantly altering islet graft potency. The facile nature of these glucocorticoid-doped PDMS constructs allows for the optimization of targeted dose delivery with wide applicability in cell and tissue transplantation.

Original languageEnglish (US)
Pages (from-to)2250-2261
Number of pages12
JournalTissue Engineering - Part A
Volume21
Issue number15-16
DOIs
StatePublished - Aug 1 2015

Fingerprint

Islets of Langerhans Transplantation
Polydimethylsiloxane
Dexamethasone
Modulation
Inflammation
Grafts
Glucocorticoids
Transplants
Anti-Inflammatory Agents
Transplantation (surgical)
Tissue Transplantation
Macrophage Activation
Macrophages
Cell Transplantation
Endotoxins
Scaffolds
baysilon
Monocytes
Chemical activation
Tissue

ASJC Scopus subject areas

  • Bioengineering
  • Biochemistry
  • Biomedical Engineering
  • Biomaterials

Cite this

Controlled Release of Dexamethasone from Organosilicone Constructs for Local Modulation of Inflammation in Islet Transplantation. / Weaver, Jessica D.; Song, Yun; Yang, Ethan Y.; Ricordi, Camillo; Pileggi, Antonello; Buchwald, Peter; Stabler, Cherie L.

In: Tissue Engineering - Part A, Vol. 21, No. 15-16, 01.08.2015, p. 2250-2261.

Research output: Contribution to journalArticle

Weaver, Jessica D. ; Song, Yun ; Yang, Ethan Y. ; Ricordi, Camillo ; Pileggi, Antonello ; Buchwald, Peter ; Stabler, Cherie L. / Controlled Release of Dexamethasone from Organosilicone Constructs for Local Modulation of Inflammation in Islet Transplantation. In: Tissue Engineering - Part A. 2015 ; Vol. 21, No. 15-16. pp. 2250-2261.
@article{bfc9461e8416425e820205b3adad658a,
title = "Controlled Release of Dexamethasone from Organosilicone Constructs for Local Modulation of Inflammation in Islet Transplantation",
abstract = "Inflammation is a significant detriment to the engraftment of cells and tissues, particularly for islet transplantation, where a low tolerance for the inflammatory milieu results in significant graft loss. Local treatment with anti-inflammatories, such as glucocorticoids, provides the benefits of site-targeted delivery with minimization of the broad side effects associated with systemic delivery. Polydimethylsiloxane (PDMS) is a flexible platform that is capable of providing sustained delivery of hydrophobic drugs. Here, we evaluated the capacity of PDMS constructs loaded with the anti-inflammatory glucocorticoid dexamethasone (Dex) to locally mitigate inflammation in islet grafts. Dex-PDMS constructs, fabricated in rod or disk geometries, demonstrated prolonged and sustained release at therapeutically relevant levels. In vitro, Dex-PDMS constructs inhibited endotoxin-induced human monocyte and macrophage activation, but they did not impair islet viability or function. Dex-PDMS rods, co-transplanted with islet-seeded scaffolds in a murine model, demonstrated suppression of host inflammatory responses during early- and late-phase engraftment, without significantly altering islet graft potency. The facile nature of these glucocorticoid-doped PDMS constructs allows for the optimization of targeted dose delivery with wide applicability in cell and tissue transplantation.",
author = "Weaver, {Jessica D.} and Yun Song and Yang, {Ethan Y.} and Camillo Ricordi and Antonello Pileggi and Peter Buchwald and Stabler, {Cherie L.}",
year = "2015",
month = "8",
day = "1",
doi = "10.1089/ten.tea.2014.0487",
language = "English (US)",
volume = "21",
pages = "2250--2261",
journal = "Tissue Engineering - Part A",
issn = "1937-3341",
publisher = "Mary Ann Liebert Inc.",
number = "15-16",

}

TY - JOUR

T1 - Controlled Release of Dexamethasone from Organosilicone Constructs for Local Modulation of Inflammation in Islet Transplantation

AU - Weaver, Jessica D.

AU - Song, Yun

AU - Yang, Ethan Y.

AU - Ricordi, Camillo

AU - Pileggi, Antonello

AU - Buchwald, Peter

AU - Stabler, Cherie L.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Inflammation is a significant detriment to the engraftment of cells and tissues, particularly for islet transplantation, where a low tolerance for the inflammatory milieu results in significant graft loss. Local treatment with anti-inflammatories, such as glucocorticoids, provides the benefits of site-targeted delivery with minimization of the broad side effects associated with systemic delivery. Polydimethylsiloxane (PDMS) is a flexible platform that is capable of providing sustained delivery of hydrophobic drugs. Here, we evaluated the capacity of PDMS constructs loaded with the anti-inflammatory glucocorticoid dexamethasone (Dex) to locally mitigate inflammation in islet grafts. Dex-PDMS constructs, fabricated in rod or disk geometries, demonstrated prolonged and sustained release at therapeutically relevant levels. In vitro, Dex-PDMS constructs inhibited endotoxin-induced human monocyte and macrophage activation, but they did not impair islet viability or function. Dex-PDMS rods, co-transplanted with islet-seeded scaffolds in a murine model, demonstrated suppression of host inflammatory responses during early- and late-phase engraftment, without significantly altering islet graft potency. The facile nature of these glucocorticoid-doped PDMS constructs allows for the optimization of targeted dose delivery with wide applicability in cell and tissue transplantation.

AB - Inflammation is a significant detriment to the engraftment of cells and tissues, particularly for islet transplantation, where a low tolerance for the inflammatory milieu results in significant graft loss. Local treatment with anti-inflammatories, such as glucocorticoids, provides the benefits of site-targeted delivery with minimization of the broad side effects associated with systemic delivery. Polydimethylsiloxane (PDMS) is a flexible platform that is capable of providing sustained delivery of hydrophobic drugs. Here, we evaluated the capacity of PDMS constructs loaded with the anti-inflammatory glucocorticoid dexamethasone (Dex) to locally mitigate inflammation in islet grafts. Dex-PDMS constructs, fabricated in rod or disk geometries, demonstrated prolonged and sustained release at therapeutically relevant levels. In vitro, Dex-PDMS constructs inhibited endotoxin-induced human monocyte and macrophage activation, but they did not impair islet viability or function. Dex-PDMS rods, co-transplanted with islet-seeded scaffolds in a murine model, demonstrated suppression of host inflammatory responses during early- and late-phase engraftment, without significantly altering islet graft potency. The facile nature of these glucocorticoid-doped PDMS constructs allows for the optimization of targeted dose delivery with wide applicability in cell and tissue transplantation.

UR - http://www.scopus.com/inward/record.url?scp=84938503359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938503359&partnerID=8YFLogxK

U2 - 10.1089/ten.tea.2014.0487

DO - 10.1089/ten.tea.2014.0487

M3 - Article

C2 - 26027872

AN - SCOPUS:84938503359

VL - 21

SP - 2250

EP - 2261

JO - Tissue Engineering - Part A

JF - Tissue Engineering - Part A

SN - 1937-3341

IS - 15-16

ER -